Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia

Aim: To compare clinical characteristics and identify factors predictive of resistance to initial treatment with methotrexate-folinic acid (MTX-FA) in women with low-risk gestational trophoblastic neoplasia (GTN). Methods: Retrospective chart reviews were conducted in patients diagnosed with low-ris...

Full description

Saved in:
Bibliographic Details
Main Author: Phianpiset R.
Other Authors: Mahidol University
Format: Article
Published: 2023
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/85518
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
id th-mahidol.85518
record_format dspace
spelling th-mahidol.855182023-06-19T00:43:22Z Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia Phianpiset R. Mahidol University Medicine Aim: To compare clinical characteristics and identify factors predictive of resistance to initial treatment with methotrexate-folinic acid (MTX-FA) in women with low-risk gestational trophoblastic neoplasia (GTN). Methods: Retrospective chart reviews were conducted in patients diagnosed with low-risk GTN who were treated with MTX-FA at Siriraj Hospital between 2002 and 2018. Demographic data, disease characteristics, treatment response, toxicity, and data of the subsequent pregnancy were collected and analyzed. Groups of patients who were responsive or resistant to treatment were compared. Stepwise logistic regression analysis was used to identify factors predictive of resistance to methotrexate chemotherapy. Results: Totally, 113 patients were eligible for analysis. The primary remission rate was 55.8% with first-line MTX-FA. All other patients achieved remission by subsequent treatment with actinomycin D or multiple-agent chemotherapy. Relapse of disease occurred in 4.4% and the overall survival rate was 99.1%. Univariate analysis showed that pretreatment serum hCG, neutrophil-to-lymphocyte ratio at baseline, and serum hCG ratio of the first three consecutive cycles (C) were significantly associated with resistance to MTX-FA. Independent factors that predict failure to respond to first-line MTX-FA were pretreatment serum hCG ≥15,000 IU/L, a less than 4.8-fold reduction of serum hCG between cycle 1 and cycle 2 (C1/C2), and a less than seven-fold reduction of serum hCG from cycle 2 to cycle 3 (C2/C3). Conclusions: First-line MTX-FA treatment is effective in 55.8% of patients. Pretreatment serum hCG, and serum hCG ratio between consecutive treatment cycles can predict initial treatment failure. 2023-06-18T17:43:22Z 2023-06-18T17:43:22Z 2022-10-01 Article Asia-Pacific Journal of Clinical Oncology Vol.18 No.5 (2022) , e495-e506 10.1111/ajco.13774 17437563 17437555 35253996 2-s2.0-85125659219 https://repository.li.mahidol.ac.th/handle/123456789/85518 SCOPUS
institution Mahidol University
building Mahidol University Library
continent Asia
country Thailand
Thailand
content_provider Mahidol University Library
collection Mahidol University Institutional Repository
topic Medicine
spellingShingle Medicine
Phianpiset R.
Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia
description Aim: To compare clinical characteristics and identify factors predictive of resistance to initial treatment with methotrexate-folinic acid (MTX-FA) in women with low-risk gestational trophoblastic neoplasia (GTN). Methods: Retrospective chart reviews were conducted in patients diagnosed with low-risk GTN who were treated with MTX-FA at Siriraj Hospital between 2002 and 2018. Demographic data, disease characteristics, treatment response, toxicity, and data of the subsequent pregnancy were collected and analyzed. Groups of patients who were responsive or resistant to treatment were compared. Stepwise logistic regression analysis was used to identify factors predictive of resistance to methotrexate chemotherapy. Results: Totally, 113 patients were eligible for analysis. The primary remission rate was 55.8% with first-line MTX-FA. All other patients achieved remission by subsequent treatment with actinomycin D or multiple-agent chemotherapy. Relapse of disease occurred in 4.4% and the overall survival rate was 99.1%. Univariate analysis showed that pretreatment serum hCG, neutrophil-to-lymphocyte ratio at baseline, and serum hCG ratio of the first three consecutive cycles (C) were significantly associated with resistance to MTX-FA. Independent factors that predict failure to respond to first-line MTX-FA were pretreatment serum hCG ≥15,000 IU/L, a less than 4.8-fold reduction of serum hCG between cycle 1 and cycle 2 (C1/C2), and a less than seven-fold reduction of serum hCG from cycle 2 to cycle 3 (C2/C3). Conclusions: First-line MTX-FA treatment is effective in 55.8% of patients. Pretreatment serum hCG, and serum hCG ratio between consecutive treatment cycles can predict initial treatment failure.
author2 Mahidol University
author_facet Mahidol University
Phianpiset R.
format Article
author Phianpiset R.
author_sort Phianpiset R.
title Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia
title_short Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia
title_full Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia
title_fullStr Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia
title_full_unstemmed Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia
title_sort predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia
publishDate 2023
url https://repository.li.mahidol.ac.th/handle/123456789/85518
_version_ 1781414235864039424